Activation of AURKA contributes to TKI resistance in EGFR-mutant non-small lung cancer

被引：0
|
作者：
Lee, Meng-Hsuan [1 ]
Hong, Shiao-Ya [2 ]
Kao, Yu-Rung [2 ]
Wu, Cheng-Wen [1 ]
机构：
[1] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei, Taiwan
[2] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-4756
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4756
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)
    Tan, Aaron C.
    Teh, Yi Lin
    Lai, Gillianne G. Y.
    Tan, Daniel S. W.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (06) : 431 - 435
  • [42] Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance
    Han, Ruoshuang
    Jia, Yijun
    Li, Xuefei
    Zhao, Chao
    Zhao, Sha
    Liu, Sangtian
    Liu, Yiwei
    Chen, Donglai
    Zhang, Qian
    Liu, Xiaozhen
    Shi, Jinpeng
    Li, Jiayu
    Zhou, Caicun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (03) : 1277 - 1291
  • [43] Resistance mechanisms to dual EGFR and MET inhibition in patients with EGFR-mutant MET-amplified non-small cell lung cancer
    Wang, K.
    Du, R.
    Roy, S.
    Vokes, N.
    Elamin, Y. Y.
    Hume, C. Bueno
    Skoulidis, F.
    Gay, C.
    Blumenschein, G.
    Fossella, F.
    Tsao, A.
    Lee, J. J.
    Rinsurongkawong, W.
    Rinsurongkawong, V.
    Gibbons, D.
    Vaporciyan, A.
    Zhang, J.
    Heymach, J.
    Altan, M.
    Le, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1016 - S1016
  • [44] EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report
    Martinez-Hernandez, Maria F.
    Lara-Mejia, Luis
    Izquierdo-Tolosa, Carlos
    Cabrera-Miranda, Luis
    Arrieta, Oscar
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (12)
  • [45] The EMT transcription factor TWIST1 mediates resistance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
    Yochum, Zachary A.
    Wang, Hailun
    Cades, Jessica A.
    Khetarpal, Susheel
    Huang, Eric H.
    Tran, Phouc T.
    Burns, Timothy F.
    CANCER RESEARCH, 2017, 77
  • [46] PRMT5 mediates cancer stemness and acquired drug resistance in EGFR-mutant non-small cell lung cancer
    Abe, Yoshinori
    Tanaka, Nobuyuki
    CANCER SCIENCE, 2021, 112 : 295 - 295
  • [47] Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
    Gen, Soei
    Tanaka, Ichidai
    Morise, Masahiro
    Koyama, Junji
    Kodama, Yuta
    Matsui, Akira
    Miyazawa, Ayako
    Hase, Tetsunari
    Hibino, Yoshitaka
    Yokoyama, Toshihiko
    Kimura, Tomoki
    Yoshida, Norio
    Sato, Mitsuo
    Hashimoto, Naozumi
    BMC CANCER, 2022, 22 (01)
  • [48] Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer
    Chen, Lanyi Nora
    Ma, Xin
    Herzberg, Benjamin
    Henick, Brian S.
    Biswas, Anup K.
    Acharyya, Swarnali
    Shu, Catherine A.
    ONCOLOGIST, 2024,
  • [49] Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-Small Cell Lung Cancer Cells
    Gao, Wen
    Wang, Michael
    Wang, Li
    Lu, Haibo
    Wu, Shuhong
    Dai, Bingbing
    Ou, Zhishuo
    Zhang, Liang
    Heymach, John V.
    Gold, Kathryn A.
    Minna, John
    Roth, Jack A.
    Hofstetter, Wayne L.
    Swisher, Stephen G.
    Fang, Bingliang
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (09):
  • [50] Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
    Soei Gen
    Ichidai Tanaka
    Masahiro Morise
    Junji Koyama
    Yuta Kodama
    Akira Matsui
    Ayako Miyazawa
    Tetsunari Hase
    Yoshitaka Hibino
    Toshihiko Yokoyama
    Tomoki Kimura
    Norio Yoshida
    Mitsuo Sato
    Naozumi Hashimoto
    BMC Cancer, 22
12345